Thryv Therapeutics to Participate in the UBS Global Biopharma Conference in London
Advancing Precision SGK1 Inhibitors at the Intersection of Electrical and Structural Heart Disease SAN FRANCISCO, Nov. 12, 2026 /PRNewswire/ -- Thryv Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.